(Q44567975)

4 December 2017

title

Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial (English)

1 reference

4 December 2017

1 reference

1 reference

2

1 reference

4 December 2017

Judith Hsia

1

1 reference

4 December 2017

Mark Tripputi

series ordinal

3

1 reference

4 December 2017

Barbara V Howard

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

published in

American Heart Journal

1 reference

4 December 2017

volume

146

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

439-445

1 reference

Obesity, mortality and cardiovascular disease in the Münster Heart Study (PROCAM).

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Cardiovascular morbidity and mortality associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Women's angiographic vitamin and estrogen trial: design and methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Lipid-lowering interventions in angiographic trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Prognostic significance of progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900227-8

10.1016/S0002-8703(03)00227-8

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference